TL;DR
This study reveals that a long non-coding RNA, uc.339, is upregulated in non-small cell lung cancer (NSCLC) and promotes tumor growth by "entrapping" tumor-suppressor microRNAs (miRNAs). This mechanism leads to the upregulation of Cyclin E2, a protein that drives cancer progression, and is regulated by the tumor suppressor TP53.
What Problem Does This Paper Address?
The role of long non-coding RNAs (lncRNAs), particularly transcribed ultraconserved regions (T-UCRs), in cancer is still largely unknown. While some T-UCRs have been implicated in carcinogenesis, their precise mechanisms of action and the factors controlling their expression in cancer remain elusive. This paper focuses on uc.339, a T-UCR, to understand its role in non-small cell lung cancer (NSCLC) and to elucidate its molecular mechanisms. Specifically, the authors aim to determine if uc.339 is dysregulated in NSCLC, if it acts as an oncogene, how it functions at a molecular level, and if the well-known tumor suppressor TP53 is involved in its regulation.
Methods
The researchers employed a multi-pronged approach:
- Quantitative Real-Time PCR (qRT-PCR): Used to measure the expression levels of uc.339 and various miRNAs in tumor and non-tumor tissues, as well as in cell lines.
- Bioinformatics Analysis: RNAhybrid was used to predict potential miRNA binding sites within the uc.339 transcript. RNAfold and CentroidFold were used to predict secondary RNA structures.
- Cell-based Assays:
- Cell Viability Assays: Assessed the impact of uc.339 modulation on cancer cell survival.
- Scratch Migration Assays: Evaluated the effect of uc.339 on cancer cell motility.
- Cell-Cycle Analysis: Determined how uc.339 affects cell cycle progression.
- Western Blotting: Measured protein levels of key molecules like Cyclin E2, cleaved PARP, and Vinculin.
- Cytoplasmic/Nuclear Fractionation: Determined the cellular localization of uc.339.
- Fluorescent In Situ Hybridization (FISH): Visualized the localization of uc.339 and miRNAs within cells.
- CRISPR/Cas9 Gene Editing: Generated cell lines with specific deletions in the uc.339 transcript to study the functional importance of miRNA binding sites.
- In Vivo Xenograft Models: Used mouse models to assess the oncogenic potential of uc.339 in a living system.
- Luciferase Reporter Assays: Validated direct targeting of CCNE2 by specific miRNAs.
- Chromatin Immunoprecipitation (ChIP): Investigated the binding of TP53 to predicted regulatory regions of uc.339.
- RNA Immunoprecipitation (RIP): Isolated uc.339-miRNA complexes to study their interaction.
- Affymetrix mRNA Array Analysis: Performed a global analysis of gene expression changes induced by uc.339.
Datasets
- TCGA (The Cancer Genome Atlas) Database: RNA-seq data from 210 NSCLC patients was used to correlate uc.339 expression with overall survival.
- Primary NSCLC Samples: 30 paired tumor and adjacent non-tumor lung tissues were used for expression analysis.
- NSCLC Cell Lines: A549, H460, and H1299 (lung adenocarcinoma/large cell lung cancer) and LoVo (colorectal adenocarcinoma) cell lines were used extensively for in vitro experiments.
Key Insights and Ideas
- "Entrapping" Mechanism: The most novel finding is the proposed "entrapping" mechanism, where uc.339 sequesters miRNAs without causing their degradation. This is distinct from typical miRNA sponge mechanisms and suggests a new mode of lncRNA-miRNA interaction.
- TP53 as a Regulator: The discovery that the tumor suppressor TP53 directly silences uc.339 provides a crucial link between a well-known cancer-related gene and the novel oncogenic lncRNA. This suggests that loss of TP53 function in cancer could lead to uc.339 activation.
- Oncogenic Axis: The study establishes a clear oncogenic axis: TP53 loss -> uc.339 upregulation -> miRNA "entrapping" -> CCNE2 upregulation -> increased tumor growth and migration.
- Multiple miRNA Targets: uc.339 doesn't just interact with one miRNA but appears to "trap" multiple tumor-suppressor miRNAs (miR-339, miR-663b, and miR-95) simultaneously, amplifying its oncogenic effect.
- Functional Significance of TREs: The identification of "trapping-related elements" (TREs) within uc.339, which influence its secondary structure and miRNA binding, highlights the complex regulatory role of lncRNA structure.
Key Results
- Upregulation in NSCLC: uc.339 expression was significantly higher in NSCLC tumors compared to adjacent non-tumor tissue.
- Prognostic Value: High uc.339 expression in NSCLC patients correlated with significantly lower overall survival.
- Oncogenic Role: Overexpression of uc.339 promoted cancer cell viability and migration in vitro, and accelerated tumor growth in vivo. Silencing uc.339 had the opposite effect.
- miRNA Sequestration: uc.339 was shown to bind to miR-339-3p, miR-663b-3p, and miR-95-5p. Overexpression of uc.339 led to downregulation of these miRNAs, while silencing uc.339 led to their upregulation.
- CCNE2 Upregulation: uc.339 overexpression led to increased levels of Cyclin E2 (CCNE2) protein, a known driver of cancer progression. This effect was mediated by the sequestration of the miRNAs that normally target CCNE2.
- TP53 Regulation: TP53 was found to directly bind to regulatory regions upstream of uc.339 and inhibit its expression. Conversely, TP53 knockdown led to uc.339 upregulation.
- Reversal of Oncogenic Effects: Restoration of functional TP53 in cancer cells reversed the oncogenic effects of uc.339, including miRNA downregulation and CCNE2 upregulation.
Limitations and Future Work
- "Entrapping" vs. ceRNA: While the study proposes the "entrapping" mechanism, the authors acknowledge that the precise molecular details of how uc.339 "hides" miRNAs are not fully elucidated. Further research is needed to understand the structural changes and interactions involved.
- Other Interactions: The authors suggest that uc.339 might interact with other miRNAs or act as an enhancer RNA (eRNA) for other transcripts, which warrants further investigation.
- TP53 Mutants: The study focused on wild-type TP53. Investigating how mutated TP53 affects uc.339 expression and the downstream pathway would be valuable.
- In Vivo Validation of "Entrapping": While the study provides strong in vitro evidence for the "entrapping" mechanism, further in vivo validation of this specific interaction would strengthen the findings.
- Clinical Translation: While uc.339 shows prognostic value, its potential as a therapeutic target or biomarker needs further exploration in larger clinical cohorts.
Summary updated